Trial on ceftazidime-avibactam in blood cancer patients
Treatments studied
Part of Blood & lymphatic, Cancer, Infections clinical trials.
This study looks at how well an antibiotic called ceftazidime-avibactam (CAZ-AVI) works in people with blood cancers or those who have had a stem cell transplant. It aims to find the right dose and see if the bacteria become resistant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 16 years old or older
- You have a blood cancer (like leukemia, lymphoma, multiple myeloma, or MDS) or have had a stem cell transplant
- Your doctor has prescribed ceftazidime-avibactam for a suspected or confirmed bacterial infection
- You are expected to take this antibiotic for at least 72 hours
- You agree to have extra blood tests and samples taken to check drug levels and bacteria
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two antibiotics (ceftolozane/tazobactam vs. piperacillin/tazobactam) for treating a bloodstream infection in people with blood cancer who have a very low white blood cell count and a fever. The goal is to see which antibiotic works better.
This trial compares two IV antibiotics (aztreonam and avibactam) against the best available treatment for serious gram-negative infections. It may help people who are hospitalized and need IV antibiotics, especially when the infection is caused by certain gram-negative bacteria.
This study tests an antibiotic called ceftazidime-avibactam for people with serious infections like bloodstream infections or pneumonia that started in the hospital or from a breathing machine. It aims to start treatment quickly after identifying the bacteria.
This trial tests whether an antibiotic called ceftazidime-avibactam (CAZ-AVI) can help patients with blood cancers who have a fever and very low infection-fighting white blood cells. It may be an option for people whose doctors plan to use this specific antibiotic to treat their fever.
This trial tests two different schedules of a combination of antibiotics (ceftazidime-avibactam plus aztreonam) for people with serious infections caused by bacteria that are hard to treat. It aims to find the best way to give these medicines.
This trial compares different ways of giving the antibiotic ceftazidime/avibactam to see which works best. It is for people with infections caused by a type of bacteria that is hard to treat (called multidrug-resistant) but still responds to this medicine.
Hear when a new Gram-Negative Bacterial Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.